Navigation Links
Perceived cancer risks may not reflect actual risks or prevention needs
Date:5/14/2009

ORLANDO (May 14, 2009)Working with a population of individuals at risk for gastrointestinal cancers, researchers at Fox Chase Cancer Center have learned that many people misjudge their actual degree of cancer risk and, therefore, their true need for prevention support. Strategies for accurately assessing cancer risk are critical for appropriately targeting educational, counseling, and diagnostic resources to prevent cancer in as many individuals as possible, the investigators say.

The study, to be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology, evaluated participants in the Gastrointestinal Tumor Risk Assessment Program at Fox Chase.

With the growth in genetic cancer risk assessment in recent years, Fox Chase clinicians and scientists have seen increasing numbers of patients enrolling in the Center's risk assessment programs, including those for breast, ovarian, melanoma, prostate, and gastrointestinal cancers. Risk for gastrointestinal cancers, the focus of the current study, is established through family and personal histories of gastrointestinal cancers and/or colorectal polyps, as well as genetic testing.

"The goal of our study was to improve how we think about and direct our prevention resources," says Michael Hall, M.D., medical oncologist at Fox Chase and lead author on the study. "We examined clinical cancer prevention needs among individuals seeking gastrointestinal risk evaluation, including in our assessment their estimated personal risk, risk beliefs, and interest in genetic testing."

The study evaluated 398 individuals from 278 families enrolled in the Gastrointestinal Tumor Risk Assessment Program at Fox Chase over a nine-year period. The program provides risk assessment to people seeking evaluation for a risk of a gastrointestinal or related cancer. Participants were required to sign an informed consent and complete a health history questionnaire prior to counseling, education, and genetic services.

Results showed that more than 17 percent of the individuals were at high-risk; 70 percent were at moderate-to-high risk; and 12 percent were at low-risk.

"One of our main findings was that, prior to counseling, individuals in the low-risk group estimated the magnitude of their cancer risk as equal to that of the high-risk group," Hall notes. "Clearly, the first step in offering clinical prevention tools to all of the individuals entering our risk assessment program is to help them to understand their actual level of risk. Only then can we recommend the appropriate prevention support."

In the Fox Chase Gastrointestinal Tumor Risk Assessment Program, low-risk individuals receive risk-factor management counseling and education related to appropriate screening. Those at moderate-to-high or high risk are offered additional prevention tools, such as intensive screening and prophylactic surgery, chemoprevention, and genetic testing.

"Preventing cancer is as important as treating cancer," says Hall, summing up his team's findings. "As information about the genetic causes of many cancers becomes more widely known, motivated people with a varying levels of concern and need come to us for risk assessment. To best serve them, we must be able to gauge their risk accurately in order to maximize the benefits of the prevention tools we offer."


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Women who are perceived as confident in job interviews also seen as lacking social skills
2. Perceived level of intimacy within a relationship predicts relational uncertainty
3. Perceived discrimination affects screening rates
4. Possession Is Nine-Tenths the Perceived Value
5. Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed
6. Price Plays Part in Perceived Power of Medication
7. Patients perceived cancer care unaffected by lower Medicare reimbursements
8. Gene Screen May Predict Colon Cancers Return
9. May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO
10. Genomic Healths Oncotype DX(R) Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients
11. MITs implantable device offers continuous cancer monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Melbourne, Australia (PRWEB) , ... February 24, 2017 , ... ... Press AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema ... post-traumatic stress disorder and his attempts to overcome them. , Schanssema, initially unsure ...
(Date:2/24/2017)... ... 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer ... started as the Chairman of the Management Committee when IFN was originally formed in ... recruitment of investor/owners and development of the business plan. He became the first ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... Feb. 23, 2017  This report analyzes the worldwide ... following Products: Intermediates, Analytical, and Others. ... include Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive ... Europe , and Rest of World. ... 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) today announced ... Directors that will be submitted to the 2017 Annual ... the company,s three largest shareholders at the end of ... seat on the Nomination Committee, and the Chairman of ... was as follows:  Anders ...
Breaking Medicine Technology: